You are here » Home » Companies » Company Overview » Vaishali Pharma Ltd

Vaishali Pharma Ltd.

BSE: 535000 Sector: Others
NSE: VAISHALI ISIN Code: INE972X01014
BSE 05:30 | 01 Jan Vaishali Pharma Ltd
NSE 00:00 | 21 Jan 37.50 -0.85
(-2.22%)
OPEN

39.00

HIGH

39.80

LOW

37.00

OPEN
PREVIOUS CLOSE
VOLUME
52-Week high 0.00
52-Week low 0.00
P/E
Mkt Cap.(Rs cr) 0
Buy Price
Buy Qty
Sell Price
Sell Qty
OPEN
CLOSE
VOLUME
52-Week high 0.00
52-Week low 0.00
P/E
Mkt Cap.(Rs cr) 0
Buy Price
Buy Qty
Sell Price
Sell Qty

Vaishali Pharma Ltd. (VAISHALI) - Chairman Speech

Company chairman speech

Dear Shareowners

We are in the throes of a global pandemic and the world is looking up to the healthcareindustry to develop vaccines treatments diagnostics and products that will see itthrough the COVID-19 crisis. The novel coronavirus outbreak has demonstrated that ifhumanity is to survive as a species it is imperative that there is equitable access toall essential health products and technologies without distinction of race religionpolitical belief and economic or social condition. Universal access to quality healthcarefor all is non-negotiable.

Global as well as domestic economic growth continued to be subdued in FY 2019-20 owingto varied macroeconomic uncertainties. To add fuel to re the sudden outbreak of theCOVID-19 pandemic caused rampant disruptions across supply chains and manufacturingactivities bringing economic activity to a standstill. Countries were locked downcompletely businesses stopped inde nitely and the wheels of the economy started turningbackwards.

It's the start of another fiscal and with immense pleasure I share with you ourCompany's performance in FY 2019-20. In the last six months the world has witnessedunprecedented events adopted to a new normal and has improvised ways to ensure businesscontinuity. Amidst such volatility we have once again delivered on our promise despitesluggish economic growth.

I am pleased to present the 13th Annual Report for the financial year2019-20. It was a year of sustained growth and resilience. Our resilience was derived fromthe ability to identify opportunities attaining product registration investing inenduring relationships and prudent finance management across geographies and industrycycles.

With our headquarters located admidst the economic hub of India Mumbai we haveestablished our o ces in Vietnam. Further we are widening our reach overseas we have madea joint venture with D.R. Congo & Kenya based company. Our 150 + formulation brandsare being marketed in multiple countries. Our synergistic collaboration with WHO-GMPmanufacturing facilities is backed by excellent rapport with our clients.

With a clear vision to spread our wings across the globe we are currently exposed forFormulations Surgical & APIs and veterinary to Russia Dubai Zimbabwe NigeriaKenya Sri Lanka Ukraine Ethiopia Costa Rica Iraq Lebanon DR Congo MyanmarTajikistan Bangladesh Kazakhstan Cameroon Jordan Burkina-Faso Nicaragua YemenCambodia Congo Tanzania Vietnam C.A.R. and Guinea-Bissau.

The next few months will be di cult but the company is strong with deep relationshipswith customers and partners enviable scale a diversi ed business mix a robust andresilient business model and strong nancials. It is well positioned to weather the stormsahead and take advantage of opportunities that come up during the downturn to acquire newcapabilities and gain market share. In the post pandemic world pharmaceutical industrywill play an ever larger role in helping enterprises adapt to the new normal anddifferentiate themselves. Your company is well poised to take the lead in partneringcustomers to recover and rebound on to their growth and transformation journeys.

I take this opportunity to thank each one of you valued customers employees andsuppliers for the faith placed in the company and look forward to your continued support.

.